Lexicon Pharmaceuticals | LXRX - Operating Expenses

Stock Price
1.60
Daily Change
-0.05 -3.03%
Monthly
0%
Yearly
133.58%
Q2 Forecast
1.60

Lexicon Pharmaceuticals reported $20.27M in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
Abbott USD 9.31B 104M Mar/2026
Acadia Pharmaceuticals USD 266.6M 23.72M Dec/2025
Agios Pharmaceuticals USD 130.77M 10.77M Mar/2026
Akebia Therapeutics USD 63.08M 8.26M Dec/2025
Alnylam Pharmaceuticals USD 898.54M 66.78M Mar/2026
AstraZeneca USD 8.18B 4.35B Mar/2026
BioMarin Pharmaceutical USD 636.56M 39.61M Mar/2026
Coherus Biosciences USD 51.83M 2.48M Dec/2025
Eli Lilly USD 10.02B 285M Mar/2026
Esperion Therapeutics USD 83.21M 14.06M Dec/2025
Halozyme Therapeutics USD 211.07M 74.73M Dec/2025
Illumina USD 852M 51M Mar/2026
Insmed USD 513.55M 109.86M Dec/2025
Ironwood Pharmaceuticals USD 57.33M 8.63M Dec/2024
J&J USD 17.44B 1.53B Mar/2026
Lexicon Pharmaceuticals USD 20.27M 6.1M Dec/2025
MacroGenics USD 53.32M 13.68M Dec/2025
MannKind USD 119.64M 56.29M Dec/2025
Merck USD 18.17B 8.01B Mar/2026
Moderna USD 1.78B 242M Mar/2026
Novartis USD 9.29B 507M Mar/2026
PTC Therapeutics USD 246.3M 38.78M Dec/2025
Puma Biotechnology USD 49.26M 3.2M Jun/2024
Sarepta Therapeutics USD 853.02M 390.78M Dec/2025
Thermo Fisher Scientific USD 9.09B 821M Mar/2026
Ultragenyx Pharmaceutical USD 305M 16M Mar/2026
United Therapeutics USD 5.9B 5.1B Mar/2026
Vanda Pharmaceuticals USD 466M 20.33M Sep/2025